Randomized Controlled Trial

Citations 81-86 of 86 total displayed.

Past content (since Nov 1998):

Original Contributions
Clinical Significance of the Multiple Sclerosis Functional Composite: Relationship to Patient-Reported Quality of Life

Deborah M. Miller; Richard A. Rudick; Gary Cutter; Monika Baier; Jill S. Fischer
Arch Neurol 2000; 57: 1319-1324. [Abstract] [Full text] [PDF]  

Neurotherapeutics
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics

Richard A. Rudick
Arch Neurol 1999; 56: 1079-1084. [Extract] [Full text] [PDF]  

Original Contributions
A Randomized Placebo-Controlled Comparative Trial of Gabapentin and Propranolol in Essential Tremor

Alexandre Gironell; Jaime Kulisevsky; Manel Barbanoj; Dolores López-Villegas; Gonzalo Hernández; Berta Pascual-Sedano
Arch Neurol 1999; 56: 475-480. [Abstract] [Full text] [PDF]  

Editorials
New Treatments in Alzheimer Disease and the Continued Need for Placebo-Controlled Trials

Martin R. Farlow
Arch Neurol 1998; 55: 1396-1398. [Extract] [Full text] [PDF]  

Special Articles
Is the Placebo Control Obsolete in a World After Donepezil and Vitamin E?

Jason H. T. Karlawish; Peter J. Whitehouse
Arch Neurol 1998; 55: 1420-1424. [Abstract] [Full text] [PDF]  

Special Articles
Clinical Research Designs for Emerging Treatments for Alzheimer Disease: Moving Beyond Placebo-Controlled Trials

David Knopman; Jeffrey Kahn; Steven Miles
Arch Neurol 1998; 55: 1425-1429. [Abstract] [Full text] [PDF]  

[First page]   [Previous page]   Pages: 1 2 3 4 5 6 7 8 9